Georgia's Online Cancer Information Center

Colon/Rectal Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Colon/Rectal Cancer
Cancer Type = Colon/Rectal Cancer
There are currently 40 active Colon/Rectal Cancer clinical trials in Georgia.
2.
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer
NCT ID
NCT04943900
Protocol IDs
CA102-003
NCI-2021-09090
3.
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCT ID
NCT05091346
Protocol IDs
E7386-G000-201
NCI-2022-02226
2021-001568-10
KEYNOTE-C83
4.
NCORP Trial
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT04607421
Protocol IDs
C4221015
NCI-2021-01687
2020-001288-99
Treatment Sites (1)
5.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
6.
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCT ID
NCT03656718
Protocol IDs
CA209-8KX
NCI-2018-02324
2018-001585-42
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCT ID
NCT02817633
Protocol IDs
4020-01-001
NCI-2016-01254
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04660812
Protocol IDs
ARC-9
NCI-2021-02881
2020-005386-13
10.
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Cancer Type
Bile Duct Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Neuroendocrine Tumor, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT02568267
Protocol IDs
RXDX-101-02
NCI-2015-01848
Treatment Sites (2)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04264702
Protocol IDs
20-041-NCP
NCI-2020-03933
12.
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
13.
NCORP Trial
Circulating Tumor DNA Testing in Predicting Treatment for Patients with Stage IIA Colon Cancer After Surgery, COBRA Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04068103
Protocol IDs
NRG-GI005
NRG-GI005
NCI-2019-01068
Treatment Sites (1)
14.
Combination Chemotherapy with or without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Cancer Type
Cancer-Related Syndrome, Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT02912559
Protocol IDs
A021502
A021502
NCI-2016-01417
A021502
15.
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT02997228
Protocol IDs
NRG-GI004
NRG-GI004
NCI-2016-01961
NRG-GI004/S1610
Treatment Sites (1)
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
16.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
17.
NCORP Trial
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04137107
Protocol IDs
A221805
A221805
A221805
NCI-2019-04727
18.
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Cancer Type
Colon/Rectal Cancer, Pancreatic Cancer
NCT ID
NCT03485209
Protocol IDs
SGNTV-001
NCI-2018-00676
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
NCORP Trial
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT01349881
Protocol IDs
S0820
U10CA037429
NCI-2012-02067
Treatment Sites (8)
Dwight David Eisenhower Army Medical Center
Augusta
Erik Rupard
706-787-2100
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT04136002
Protocol IDs
02-GI-002
NCI-2021-00076
21.
Genetic Testing in Screening Patients with Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03765736
Protocol IDs
ACCRU-GI-1611
NCI-2018-02862
22.
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Cancer Type
Colon/Rectal Cancer, Esophogeal Cancer, Stomach/ Gastric Cancer
NCT ID
NCT03798626
Protocol IDs
CVPM087A2101
NCI-2019-04426
2018-003952-19
23.
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients with Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT03337087
Protocol IDs
ACCRU-GI-1603
NCI-2017-01976
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
24.
Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03983993
Protocol IDs
Winship4517-18
NCI-2018-02757
IRB00107377
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
NCORP Trial
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type
Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (10)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Piedmont Fayette Hospital
Fayetteville
404-851-2340
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
26.
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma
NCT ID
NCT03195699
Protocol IDs
SM_CP2016-0842
NCI-2022-01107
27.
Panitumumab, Regorafenib, or TAS-102, in Treating Patients with Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT03992456
Protocol IDs
ACCRU-GI-1623
NCI-2019-03306
28.
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type
Colon/Rectal Cancer, Pancreatic Cancer, Sarcoma, Solid Tumor
NCT ID
NCT03715933
Protocol IDs
Ph1 INBRX-109
NCI-2018-03556
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
29.
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04793958
Protocol IDs
849-010
NCI-2021-03009
KRYSTAL-10
30.
Prevention of Colorectal Cancer Through Multiomics Blood Testing
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT04369053
Protocol IDs
FRNM-004
NCI-2020-07736
31.
Regorafenib, with Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04117945
Protocol IDs
ACCRU-GI-1809
NCI-2019-06518
32.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
NCI-2020-06149
20193108
4R44CA250824-02
R44CA250824-01
33.
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Cancer Type
Colon/Rectal Cancer, Melanoma, Ovarian Cancer
NCT ID
NCT04837196
Protocol IDs
7517-CL-1101
NCI-2021-06479
34.
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCT ID
NCT04699188
Protocol IDs
CJDQ443A12101
NCI-2021-01594
35.
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Melanoma
NCT ID
NCT04348916
Protocol IDs
ONCR-177-101
NCI-2020-02978
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
36.
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Cancer Type
Colon/Rectal Cancer, Gynecologic Cancers
NCT ID
NCT02628067
Protocol IDs
NCT02628067
3475-158
2015-002067-41
163196
Treatment Sites (3)
37.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Ovarian Cancer
NCT ID
NCT02715284
Protocol IDs
4010-01-001
NCI-2016-01910
38.
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Neuroendocrine Tumor, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04579757
Protocol IDs
2020-012-GLOB1
NCI-2021-01887
39.
NCORP Trial NCI Priority
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type
Bladder Cancer, Brain & Spinal Cord Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Plasma cell neoplasm, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Thyroid Cancer, Unknown Primary, Uterine Cancer
NCT ID
NCT02465060
Protocol IDs
EAY131
NCI-2015-00054
EAY131-A
EAY131-B
EAY131-E
EAY131-F
EAY131-G
EAY131-H
EAY131-Q
EAY131-R
EAY131-U
EAY131-V
Treatment Sites (29)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
40.
NCORP Trial
Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer, SOLARIS Trial
Cancer Type
Colon/Rectal Cancer
NCT ID
NCT04094688
Protocol IDs
A021703
A021703
NCI-2019-01034
Treatment Sites (5)
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.